Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of SPR206 in Renal Impairment
NCT04865393Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SPR206 in gram-negative bacterial infections, sponsored by Spero Therapeutics. Primary endpoints: Time to Maximum Plasma Concentration at 36 hours, Maximum Plasma Concentration at 36 hours and 2 more. Started Jun 2021; status: completed.
02
Drugs
SPR206
03
Conditions
gram-negative bacterial infections
Beyond the preview
Go deeper on NCT04865393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04865393.